Welcome to DiagnosticON

image image

DiagnosticON: Technology Overview

We aim to assist hospitals in the US and Europe in achieving an optimal operational point - delivering maximum patient health outcomes with minimal investments and avoiding penalties.

Compared to physician judgment during discharge, DiagnosticON provides:

  • Enhanced accuracy in risk assessment, reducing incorrect decisions.
  • The ability to detect ECG patterns not readily identifiable to the human eye.
  • The capacity to discern complex patterns and interactions between ECG and patient information regarding their conditions and comorbidities, something not feasible through human introspection.
  • Speedier complex decision-making processes like discharge decisions, while providing physicians with pertinent information to guide subsequent steps.

 

Discover More
About Shape
About Shape
About Shape
About Shape
About Shape
About Shape
About Shape
About Shape

DiagnosticON AI ecosystems

We are delighted to offer three AI modules and two AI platforms, each available in two variants: either as a web-calculator or as a combination of a web-calculator and an EHR-compatible fully automated system.

 

DiagnosticON AMI

DiagnosticON AMI is an AI module designed to assess the risk of hospital readmission within 30 days after acute myocardial infarction (AMI), utilizing patient characteristics as its key predictors.

2024 /Release Date
  • Accessible through a web-based interface
  • Flexibility of integration with EHR systems
  • Option for pre-registration (exclusively available for healthcare professionals)
  • Projected Release Date: January 2024
  • Anticipated CE Mark: 2025
  • Expected FDA Approval: 2025

DiagnosticON HF

DiagnosticON HF is an AI module aimed at evaluating the risk of hospital readmission within 30 days after hospitalization for heart failure (HF), leveraging patient characteristics as its primary factors.

2024 /Release Date
  • Accessible through a web-based interface
  • Flexibility of integration with EHR systems
  • Option for pre-registration, exclusively available for healthcare professionals
  • Projected Release Date: June 2024
  • Anticipated CE Mark: 2025
  • Expected FDA Approval: 2025

DiagnosticON ECG

DiagnosticON ECG is an AI module designed to assess the risk of hospital readmission within 30 days ECG findings.

2024 /Release Date
  • Flexibility of integration with EHR systems
  • Option for pre-registration, exclusively available for healthcare professionals
  • Projected Release Date: June 2024
  • Anticipated CE Mark: 2025
  • Expected FDA Approval: 2025

DiagnosticON ECG Plus

DiagnosticON ECG Plus is an AI module designed to assess the risk of hospital readmission within 30 days after AMI and HF, utilizing patient characteristics and ECG findings..

2024 /Release Date
  • Flexibility of integration with EHR systems
  • Option for pre-registration (exclusively available for healthcare professionals)
  • Projected Release Date: January 2024
  • Anticipated CE Mark: 2025
  • Expected FDA Approval: 2025

DiagnosticON AI platform

The DiagnosticON Premium System combines AI modules for AMI and HF, integrating predictions based on patient characteristics and ECG findings.

2025 /Release Date
  • Flexibility of integration with EHR systems
  • Option for pre-registration (exclusively available for healthcare professionals)
  • Projected Release Date: January 2025
  • Anticipated CE Mark: 2026
  • Expected FDA Approval: 2026
  •  

DiagnosticON RM

DiagnosticON RM is a technology employing a remote monitoring skin patch to gather vital signs from patients suffering from Acute Myocardial Infarction (AMI) and Heart Failure (HF). The collected data is then processed by an AI system, capable of predicting serious complications. If the risk is high, the system promptly alerts healthcare professionals, facilitating early medical intervention and potentially averting severe disabilities or even death.

TBD /Release Date

More information about the technology will be revealed in due course.

Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape

Visit the investors' page for more information

Currently, nearly 6.5 million Americans over the age of 20 are living with heart failure. This figure is expected to increase to 8.5 million by 2030. An estimated 960,000 new heart failure cases are reported annually. Heart failure is responsible for about 8.5% of all heart disease-related deaths in the United States. In 2018, heart failure was mentioned in 379,800 death certificates, accounting for 13.4% of all deaths. Heart failure remains the leading cause of hospitalizations among the Medicare population. Consequently, Medicare has started implementing programs that tie payment to the quality of hospital care. This includes penalties for hospitals if patients with heart failure experience unplanned readmissions due to complications within 30 days after hospital discharge (Medicare Hospital Readmissions Reduction Program).

Watch More
image

Latest Updates

As a dynamic AI startup, we are committed to keeping you connected with the cutting-edge advancements we're making in the field. Here, we'll share our latest news, industry insights, product launches, and significant milestones. Dive in to discover how we're shaping the future of technology and driving change in the industry.

blog image

DiagnosticON Joins the NVIDIA Inception Program: A Milestone Achievement

Company Announcement Today, we are thrilled to announce that DiagnosticON has reached yet another remarkable landmark in its journey...

Read More
blog image

DiagnosticON Proudly Joins the AWS Activate Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod...

Read More
blog image

DiagnosticON Joins the ABC Founders Deep Tech Startup Support Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod...

Read More
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape

Partnership Opportunities

As a forward-thinking startup focused on leveraging Artificial Intelligence for healthcare, we are always seeking strategic alliances that can enhance our mission to revolutionize patient care. Whether you're a tech firm, healthcare provider, or research institution, there's room to collaborate and make a significant impact in the health landscape.

Universities

We are deeply committed to forging strong alliances with academic institutions as part of our innovation journey.

Hospitals

At DiagnosticON, we firmly believe in the power of collaboration and are keen on fostering strong partnerships with healthcare institutions worldwide.

MedTech&Pharma Industry

DiagnosticON Seeks Collaborative Opportunities with MedTech and Pharma Industries

Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
image

Start Your Free Trial

Pre-register now for early access to DiagnosticON